Literature DB >> 21103153

Managing bipolar depression.

Raymond Pary1, Paul R Matuschka, Susan Lewis, Steven Lippmann.   

Abstract

What should the clinician do when confronted with a patient who has depressive symptoms? Seek the proper diagnosis. Question the patient about depressive symptoms over a two-week course that interferes with social and/or occupational functioning. Determine if there is any history of mania or hypomania. Information from a significant other is extremely useful as well. Coexisting diagnoses, such as substance abuse, posttraumatic stress disorder, or medical conditions, must be ruled in or out. It is critical to include a suicide risk assessment in the evaluation. Lithium is still the gold standard for bipolar patients with its suicide preventative effects. Lamotrigine appears to have the advantage of efficacy against bipolar depression without high risk for inducing mania. Experts recommend that a mood stabilizer be used in combination with antidepressants. The tricyclic antidepressants and the monoamine oxidase inhibitors appear to have the highest risk for mania and are best avoided. Atypical antipsychotic medications are best utilized for psychotic symptoms and as adjuncts to existing antidepressants. Cognitive behavioral therapy may complement pharmacotherapy.

Entities:  

Year:  2006        PMID: 21103153      PMCID: PMC2990551     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  50 in total

Review 1.  Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder.

Authors:  O A De León
Journal:  Harv Rev Psychiatry       Date:  2001 Sep-Oct       Impact factor: 3.732

Review 2.  Atypical antipsychotics for bipolar disorder.

Authors:  Lakshmi N Yatham
Journal:  Psychiatr Clin North Am       Date:  2005-06

3.  The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s.

Authors:  J K Rybakowski; M Chlopocka-Wozniak; A Suwalska
Journal:  Bipolar Disord       Date:  2001-04       Impact factor: 6.744

Review 4.  Antidepressant properties of anticonvulsant drugs for bipolar disorder.

Authors:  Carrie L Ernst; Joseph F Goldberg
Journal:  J Clin Psychopharmacol       Date:  2003-04       Impact factor: 3.153

5.  A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year.

Authors:  Dominic H Lam; Edward R Watkins; Peter Hayward; Jenifer Bright; Kim Wright; Natalie Kerr; Gina Parr-Davis; Pak Sham
Journal:  Arch Gen Psychiatry       Date:  2003-02

6.  Suicide risk in bipolar disorder during treatment with lithium and divalproex.

Authors:  Frederick K Goodwin; Bruce Fireman; Gregory E Simon; Enid M Hunkeler; Janelle Lee; Dennis Revicki
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

Review 7.  Stereotactic cingulotomy.

Authors:  G Rees Cosgrove; Scott L Rauch
Journal:  Neurosurg Clin N Am       Date:  2003-04       Impact factor: 2.509

Review 8.  Treatment of acute bipolar depression: a review of the literature.

Authors:  M Srisurapanont; L N Yatham; A P Zis
Journal:  Can J Psychiatry       Date:  1995-11       Impact factor: 4.356

9.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.

Authors:  R Aronson; H J Offman; R T Joffe; C D Naylor
Journal:  Arch Gen Psychiatry       Date:  1996-09

10.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

Authors:  Charles DeBattista; Karl Doghramji; Matthew A Menza; Murray H Rosenthal; Ronald R Fieve
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

View more
  1 in total

1.  Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.

Authors:  Javier Garzón-Niño; María Rodríguez-Muñoz; Elsa Cortés-Montero; Pilar Sánchez-Blázquez
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.